000			02074 a2200553 4500
005			20250516143629.0
264		0	_c20140204
008			201402s 0 0 eng d
022			_a1744-7607
024	7		_a10.1517/17425255.2013.789018 _2doi
040			_aNLM _beng _cNLM
100	1		_aAgúndez, José A G
245	0	0	_aAnti-Parkinson's disease drugs and pharmacogenetic considerations. _h[electronic resource]
260			_bExpert opinion on drug metabolism & toxicology _cJul 2013
300			_a859-74 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAryl Hydrocarbon Hydroxylases _xgenetics
650	0	4	_aBenzothiazoles _xtherapeutic use
650	0	4	_aBenztropine _xtherapeutic use
650	0	4	_aBromocriptine _xtherapeutic use
650	0	4	_aCabergoline
650	0	4	_aCatechols _xtherapeutic use
650	0	4	_aCytochrome P-450 CYP1A2 _xmetabolism
650	0	4	_aCytochrome P-450 CYP1A2 Inhibitors
650	0	4	_aCytochrome P-450 CYP2B6
650	0	4	_aCytochrome P-450 CYP2C19
650	0	4	_aCytochrome P-450 CYP3A _xgenetics
650	0	4	_aErgolines _xtherapeutic use
650	0	4	_aGenetic Markers
650	0	4	_aHumans
650	0	4	_aIndans _xtherapeutic use
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aLevodopa _xtherapeutic use
650	0	4	_aLisuride _xtherapeutic use
650	0	4	_aNitriles _xtherapeutic use
650	0	4	_aParkinson Disease _xdrug therapy
650	0	4	_aPergolide _xtherapeutic use
650	0	4	_aPharmacogenetics
650	0	4	_aPramipexole
650	0	4	_aReceptors, Dopamine D2 _xgenetics
650	0	4	_aReceptors, Dopamine D3 _xgenetics
650	0	4	_aReproducibility of Results
650	0	4	_aSelegiline _xtherapeutic use
700	1		_aGarcía-Martín, Elena
700	1		_aAlonso-Navarro, Hortensia
700	1		_aJiménez-Jiménez, Félix Javier
773	0		_tExpert opinion on drug metabolism & toxicology _gvol. 9 _gno. 7 _gp. 859-74
856	4	0	_uhttps://doi.org/10.1517/17425255.2013.789018 _zAvailable from publisher's website
999			_c22650065 _d22650065